Abstract
We evaluated whether V-5 Immunitor (V5), tableted immunotherapeutic preparation comprising heatinactivated HBV antigens from pooled blood of HBV- and HCV-infected donors, may produce clinical benefit through induction of oral tolerance and reduction of immune-mediated liver injury. Once daily dose of V5 was administered per os to 10 patients with chronic hepatitis B in an open label study that lasted one month. Every patient who entered the study had elevated liver enzyme levels, which at the end of study have decreased in 100% of analyzed patients. The reduction was highly significant, from 112.4 to 44.4 U/L (P=0.00009) and 118.8 to 46.1 U/L (P=0.0032), for ALT and AST respectively. In addition, half of intent-to-treat patients who were HBV surface antigen (HBsAg) positive at study entry, became negative after one month on V5 (P=0.0098). All patients, except one, reported complete recuperation from hepatitisassociated clinical symptoms present at baseline (P=0.0016). No adverse events were observed at any time. Favorable biochemical, virological and clinical responses indicate that V5 is safe and effective means for immunotherapy of chronic hepatitis B. Placebo-controlled, randomized study is required to confirm these findings.
Keywords: Hepatitis B, Liver function test, Therapeutic vaccine, Immunomodulating supplement, per os
Letters in Drug Design & Discovery
Title: Open Label Trial of Therapeutic Hepatitis B Vaccine V-5 Immunitor (V5)Delivered by Oral Route
Volume: 4 Issue: 8
Author(s): Dendev Batdelger, Dorjiin Dandii, Vichai Jirathitikal and Aldar S. Bourinbaiar
Affiliation:
Keywords: Hepatitis B, Liver function test, Therapeutic vaccine, Immunomodulating supplement, per os
Abstract: We evaluated whether V-5 Immunitor (V5), tableted immunotherapeutic preparation comprising heatinactivated HBV antigens from pooled blood of HBV- and HCV-infected donors, may produce clinical benefit through induction of oral tolerance and reduction of immune-mediated liver injury. Once daily dose of V5 was administered per os to 10 patients with chronic hepatitis B in an open label study that lasted one month. Every patient who entered the study had elevated liver enzyme levels, which at the end of study have decreased in 100% of analyzed patients. The reduction was highly significant, from 112.4 to 44.4 U/L (P=0.00009) and 118.8 to 46.1 U/L (P=0.0032), for ALT and AST respectively. In addition, half of intent-to-treat patients who were HBV surface antigen (HBsAg) positive at study entry, became negative after one month on V5 (P=0.0098). All patients, except one, reported complete recuperation from hepatitisassociated clinical symptoms present at baseline (P=0.0016). No adverse events were observed at any time. Favorable biochemical, virological and clinical responses indicate that V5 is safe and effective means for immunotherapy of chronic hepatitis B. Placebo-controlled, randomized study is required to confirm these findings.
Export Options
About this article
Cite this article as:
Batdelger Dendev, Dandii Dorjiin, Jirathitikal Vichai and Bourinbaiar S. Aldar, Open Label Trial of Therapeutic Hepatitis B Vaccine V-5 Immunitor (V5)Delivered by Oral Route, Letters in Drug Design & Discovery 2007; 4 (8) . https://dx.doi.org/10.2174/157018007782794545
DOI https://dx.doi.org/10.2174/157018007782794545 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential for Predicting Toxicity and Response of Fluoropyrimidines in Patients
Current Drug Targets Modeling Rett Syndrome Using Human Induced Pluripotent Stem Cells
CNS & Neurological Disorders - Drug Targets Recent Androgen Receptor Antagonists in Prostate Cancer
Mini-Reviews in Medicinal Chemistry Pharmacokinetic Distribution of 67Cu(II)2[3,5-Diisopropyl(Carboxy- 14C)Salicylate]4 Among Murine Tissues
Current Medicinal Chemistry Toll-Like Receptor Agonists as Adjuvants for HIV Vaccines
Current Medicinal Chemistry Nanotechnology in Therapeutics – Current Technologies and Applications
Current Nanoscience Emerging Role of Regulatory T Cells in Gene Transfer
Current Gene Therapy Functional and Structural Benefits Induced by Omega-3 Polyunsaturated Fatty Acids During Aging
Current Neuropharmacology Molecular Targets of Mesalazine in Colorectal Cancer
Current Cancer Therapy Reviews Crosstalk Between the Autophagy-Lysosome Pathway and the Ubiquitin-Proteasome Pathway in Retinal Pigment Epithelial Cells
Current Molecular Medicine MicroRNAs (miRNAs) as Biomarker(s) for Prognosis and Diagnosis of Gastrointestinal (GI) Cancers
Current Pharmaceutical Design Effects of Blood Pressure Control in Cardiovascular Prevention
Current Pharmaceutical Design Redox Homeostasis and Epigenetics in Non-alcoholic Fatty Liver Disease (NAFLD)
Current Pharmaceutical Design Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Current Drug Safety Statins: The Holy Grail of Abdominal Aortic Aneurysm (AAA) Growth Attenuation? A Systematic Review of the Literature
Current Vascular Pharmacology Control of Inflammatory Bowel Disease and Colorectal Cancer by Synthetic Vitamin D Receptor Ligands
Current Medicinal Chemistry A Review of Inadequate and Excessive Weight Gain in Pregnancy
Current Women`s Health Reviews Peptide and Non-peptide Antagonists Targeting Endothelin Receptors in Physiology and Pathology
Current Pharmaceutical Design Schizophrenia: Redox Regulation and Volume Neurotransmission
Current Neuropharmacology Patterns of NSAIDs Use in Palestinian Mid-Territories: A Prospective Study of Ambulatory Patients in Outpatient Pharmacies
Current Clinical Pharmacology